This is the authors' abstract. We don't add key points for this paper.
Background Eliciting broad and durable vaccine-induced immunity without reformulating the established vaccines remains a practical challenge. Therefore, we evaluated oral isoprinosine (IP) as an independent adjunct to an experimental intramuscular bivalent inactivated foot-and-mouth disease (FMD) vaccine in mice and FMD-seronegative pigs. We investigated whether this regimen could sustain and prolong vaccine-associated immune responses, while retaining the original injectable formulation. Methods Mice and FMD-seronegative pigs (n = 5/group) received an experimental bivalent inactivated FMD vaccine intramuscularly on 0 days post-vaccination (dpv) with oral IP independently. Structural protein-specific ELISA, virus-neutralizing titers to FMD virus (FMDV) serotypes O and A, IgA-associated readouts (serum and saliva), cytokine and receptor transcripts in porcine peripheral blood mononuclear cells (PBMCs), post-challenge survival and body-weight kinetics (mice), and serum biochemistry (pigs) were assessed over 84 dpv. Results Oral IP increased structural protein-specific ELISA responses and virus-neutralizing titers against FMDV serotypes O and A in both species. In mice, oral IP was associated with higher serum and salivary IgA-associated readouts (measured with commercial sIgA ELISA kits that are not FMDV antigen-specific), improved survival, and reduced body-weight loss after virulent FMDV challenge. In pigs, SP ELISA and virus-neutralizing antibody responses were higher in the oral IP group than in the vaccine-only control group across the 84-day observation period, accompanied by higher serum IgA-associated signals (non-antigen-specific) than in the vaccine-only control group; increased transcript levels of the cytokines IL-2, IL-4, IL-12p40, IL-17A, IL-18, IL-23p19, and IFN-γ, and of the cytokine receptor IL-23R, in PBMCs; and no treatment-related clinical or biochemical abnormalities. Conclusions Orally administered IP enhanced and sustained the FMDV-specific systemic antibody responses and non-antigen-specific IgA-associated responses elicited by intramuscular FMD vaccination in mice and pigs, with the sustained enhancement most evident across the 84-day observation period in pigs. These findings support further evaluation of orally administered IP as an adjunct for maintaining vaccine responsiveness without reformulating the injectable vaccine.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: